Niagen Bioscience makes Tru Niagen dietary supplements and supplies the Niagen ingredient to food makers and pharmaceutical facilities. It last closed at $2.04 on Nov 17, up 1.49% on the day. The average 12-month price target from 2 analysts is $6.50 (+218.6% from the last close), with a high of $7.00 and a low of $6.00.
Only 2 firms rated NAGE in the past 90 days, not enough for a consensus
Average 12-month target
$6.50
▲ 218.6% upside
Based on 2 analysts who set a price target on NAGE in the past 90 days. The average target is $6.50, with a high of $7.00 and a low of $6.00, compared with the last close of $2.04.
Low $6.00Avg $6.50High $7.00
Blue marker: last close $2.04
Highest target$7.00
Average target$6.50
Lowest target$6.00
Latest rating changes
Freedom BrokerMaintained
Nov 6Buy$6
Canaccord GenuityTarget lowered
Nov 6Buy$9 → $7
Canaccord GenuityMaintained
Oct 31Buy$9
Date
Firm
Action
Rating
Price target
Nov 6
Freedom Broker
Maintained
Buy
$6
Nov 6
Canaccord Genuity
Target lowered
Buy
$9 → $7
Oct 31
Canaccord Genuity
Maintained
Buy
$9
Loading…
Seasonality
How NAGE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2008.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NAGE is in one of them and how their past NAGE trades turned out.
Niagen Bioscience is a bioscience company based in Los Angeles, California, focused on healthy aging. It sells Tru Niagen dietary supplements to consumers directly and through online marketplaces and distribution partners in many countries. It also supplies its Niagen ingredient, a form of vitamin B3, to food and supplement makers and to outsourcing facilities that prepare injectable products. Its pharmaceutical work on NAD+ precursors is still in research and development and does not yet generate revenue.